MB
FBRX icon

MPM BioImpact’s Forte Biosciences FBRX Stock Holding History

MPM BioImpact’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21M Sell
987,448
-13,234
-1% -$314K 1.28% 29
2026
Q1 		$25.9M Buy
+1,000,682
New +$28.8M 2% 19

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

MPM BioImpact's FBRX Position: Q2 2026 in Review

MPM BioImpact reduced its Forte Biosciences (FBRX) stake by 1.3% in Q2 2026, selling an estimated $314K and leaving 987,448 shares worth $21M. The position accounts for 1.28% of the portfolio, ranked #29.

MPM BioImpact first reported a position in FBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $25.9M in Q1 2026. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • MPM BioImpact held 987,448 shares of Forte Biosciences worth $21M as of Q2 2026.
  • MPM BioImpact sold 13,234 Forte Biosciences shares in Q2 2026, an estimated $314K.
  • Forte Biosciences made up 1.28% of MPM BioImpact's portfolio in Q2 2026, its #29 holding.
  • MPM BioImpact first reported a position in Forte Biosciences in Q1 2026 and has held it in 2 quarters since.
  • MPM BioImpact's Forte Biosciences position peaked at $25.9M in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.